The launch of biosimilar adalimumab products in the European Union in October 2018 was an important moment for health systems in serious need of cost savings on one of their top drugs for spending: Humira. Now, early data show that adalimumab biosimilars are off to a strong start in the EU market.
The launch of biosimilar adalimumab products in the European Union in October 2018 was an important moment for health systems in serious need of cost savings on one of their top drugs for spending: Humira. Now, early data reported by IQVIA show that adalimumab biosimilars are off to a strong start in the EU market.
According to IQVIA’s data, 14 countries had biosimilar adalimumab available as of November 2018: the United Kingdom, Germany, France, Spain, Italy, the Netherlands, Belgium, Sweden, Ireland, Austria, Finland, Denmark, the Czech Republic, and Slovenia. Among these nations, Germany had the most biosimilar options available, with launches of Samsung Bioepis’ Imraldi, Amgen’s Amgevita, Sandoz’s Hyrimoz, and Mylan’s Hulio. Austria and Finland, by contrast, each had just 1 biosimilar available: Amgevita.
In Germany, the number of patients taking the brand-name Humira fell in November versus the year before biosimilars launched. While some patients were switched to other agents, such as the interleukin inhibitors sekukinumab (Cosentyx) or ustekinumab (Stelara) that are often used as alternatives for patients who lose response to anti—tumor necrosis factor therapies, the greatest percentages of patients who switched away from Humira were transitioned to Imraldi (37%), Hyrimoz (15%), and Amgevita (12%).
In the United Kingdom, which was responsible for the most consumption of brand-name Humira in the European Union as of September 2018, a centralized tender broke the adalimumab market into 11 regions, and awarded shares of the market to multiple bidders. Imraldi took the greatest share, with nearly 45% of the English market. Amgevita and Sandoz were each awarded roughly one-fourth of the market, and Hulio was awarded approximately 5% of the market.
According to IQVIA, “It is Samsung with Imraldi that has won out so far in the 2 markets that matter the most: Samsung has the largest potential market in the United Kingdom and has shown the most success in acquiring Humira patients in Germany.”
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.